FDA Weighs Reclassifying Peptides on July 23-24, Opening Legal Compounding Path
Updated
Updated · WIRED · Jul 21
FDA Weighs Reclassifying Peptides on July 23-24, Opening Legal Compounding Path
3 articles · Updated · WIRED · Jul 21
Summary
July 23-24 FDA meetings will consider moving several peptides into a category that would let pharmacies legally compound custom injectable mixes, reversing a 2023 Biden-era restriction.
Industry participants expect approval despite agency scientists recommending against it, and telehealth firms and compounders have already lined up pharmacies, formulas and pricing in anticipation.
Hims & Hers bought a peptide manufacturing facility in February 2025, while testing firms say some pharmacies are spending about $100,000 per product before any rule change is finalized.
The shift would not create an immediate green light: FDA would still need to publish proposed rules and take public comment before legal sales can broadly proceed.
Demand is already spilling into a gray market of 'research-grade' peptides and early prescribing, even as some clinicians acknowledge the products lack the safety and efficacy data of approved drugs.